MA53168B1 - Anticorps anti-bcma x anti-cd3 bispécifiques et leurs utilisations - Google Patents

Anticorps anti-bcma x anti-cd3 bispécifiques et leurs utilisations

Info

Publication number
MA53168B1
MA53168B1 MA53168A MA53168A MA53168B1 MA 53168 B1 MA53168 B1 MA 53168B1 MA 53168 A MA53168 A MA 53168A MA 53168 A MA53168 A MA 53168A MA 53168 B1 MA53168 B1 MA 53168B1
Authority
MA
Morocco
Prior art keywords
bcma
bispecific
antibodies
useful
treatment
Prior art date
Application number
MA53168A
Other languages
English (en)
Other versions
MA53168A (fr
Inventor
Qian Zhang
Eric Smith
Jessica KIRSHNER
Frank DELFINO
Kara Olson
David DILILLO
Olga SINESHCHEKOVA
Original Assignee
Regeneron Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=67515169&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA53168(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharmaceuticals, Inc. filed Critical Regeneron Pharmaceuticals, Inc.
Publication of MA53168A publication Critical patent/MA53168A/fr
Publication of MA53168B1 publication Critical patent/MA53168B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001129—Molecules with a "CD" designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4214—Receptors for cytokines
    • A61K40/4215—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4224—Molecules with a "CD" designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

L'antigène de maturation des cellules B (BCMA) est exprimé en surface des plasmocytes malins. La présente invention concerne de nouveaux anticorps bispécifiques (bsAbs) qui se lient à la fois à BCMA et à CD3 et activent les lymphocytes T par l'intermédiaire du complexe CD3 en présence de cellules tumorales exprimant BCMA. Dans certains modes de réalisation, les molécules de liaison à l'antigène bispécifiques selon la présente invention sont capables d'inhiber la croissance de tumeurs exprimant BCMA. Les molécules de liaison à l'antigène bispécifiques de l'invention sont utiles pour le traitement de maladies et de troubles dans lesquels une réponse immunitaire ciblant BCMA induite ou positivement régulée est souhaitée et/ou thérapeutiquement bénéfique. Par exemple, les anticorps bispécifiques de l'invention sont utiles pour le traitement de divers cancers, notamment le myélome multiple.
MA53168A 2018-07-19 2019-07-18 Anticorps anti-bcma x anti-cd3 bispécifiques et leurs utilisations MA53168B1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862700596P 2018-07-19 2018-07-19
US201862750968P 2018-10-26 2018-10-26
US201962793645P 2019-01-17 2019-01-17
PCT/US2019/042447 WO2020018820A1 (fr) 2018-07-19 2019-07-18 Anticorps anti-bcma x anti-cd3 bispécifiques et leurs utilisations
EP19749096.4A EP3823664B1 (fr) 2018-07-19 2019-07-18 Anticorps anti-bcma x anti-cd3 bispécifiques et leurs utilisations

Publications (2)

Publication Number Publication Date
MA53168A MA53168A (fr) 2021-05-26
MA53168B1 true MA53168B1 (fr) 2025-03-28

Family

ID=67515169

Family Applications (1)

Application Number Title Priority Date Filing Date
MA53168A MA53168B1 (fr) 2018-07-19 2019-07-18 Anticorps anti-bcma x anti-cd3 bispécifiques et leurs utilisations

Country Status (34)

Country Link
US (3) US11384153B2 (fr)
EP (2) EP3823664B1 (fr)
JP (2) JP7319348B2 (fr)
KR (1) KR20210034032A (fr)
CN (1) CN112423785B (fr)
AU (1) AU2019307928B2 (fr)
BR (1) BR112021000186A2 (fr)
CL (1) CL2021000131A1 (fr)
CO (1) CO2021000188A2 (fr)
CY (2) CY1127721T1 (fr)
DK (1) DK3823664T3 (fr)
ES (1) ES3010285T3 (fr)
FI (2) FI3823664T3 (fr)
FR (1) FR25C1029I2 (fr)
HR (1) HRP20250199T1 (fr)
HU (2) HUE070224T2 (fr)
IL (1) IL279974B2 (fr)
LT (2) LT3823664T (fr)
MA (1) MA53168B1 (fr)
MD (1) MD3823664T2 (fr)
MX (2) MX2021000488A (fr)
MY (1) MY201816A (fr)
NL (1) NL301335I2 (fr)
NO (1) NO2025036I1 (fr)
PH (1) PH12021550031A1 (fr)
PL (1) PL3823664T3 (fr)
PT (1) PT3823664T (fr)
RS (1) RS66535B1 (fr)
SG (1) SG11202100252SA (fr)
SI (1) SI3823664T1 (fr)
SM (1) SMT202500044T1 (fr)
TW (1) TWI838389B (fr)
WO (1) WO2020018820A1 (fr)
ZA (1) ZA202100087B (fr)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190320633A1 (en) 2016-11-30 2019-10-24 The Jackson Laboratory Humanized mouse model with improved human innate immune cell development
KR102745676B1 (ko) 2016-12-21 2024-12-24 테네오바이오, 인코포레이티드 항-bcma 중쇄-단독 항체
CA3063588A1 (fr) 2017-06-01 2018-12-06 Regeneron Pharmaceuticals, Inc. Anticorps humains contre bet v 1 et leurs procedes d'utilisation
MX2021000532A (es) 2018-07-19 2021-04-12 Regeneron Pharma Receptores antigénicos quiméricos con especificidad para bcma y usos de estos.
TWI838389B (zh) 2018-07-19 2024-04-11 美商再生元醫藥公司 雙特異性抗-BCMAｘ抗-CD3抗體及其用途
SG11202109002XA (en) * 2019-03-21 2021-09-29 Regeneron Pharma Combination of il-4/il-13 pathway inhibitors and plasma cell ablation for treating allergy
SI3819007T1 (sl) 2019-11-11 2024-10-30 Amgen Inc. Režim odmerjanja sredstev proti BCMA
CN114929343B (zh) * 2019-12-06 2025-03-18 瑞泽恩制药公司 用双特异性抗BCMA x抗CD3抗体治疗多发性骨髓瘤的方法
TW202144425A (zh) * 2020-04-17 2021-12-01 大陸商上海翰森生物醫藥科技有限公司 特異性抗原結合分子，其製備方法及醫藥用途
WO2022002033A1 (fr) * 2020-06-30 2022-01-06 和铂医药(上海)有限责任公司 Protéine de liaison ayant des structures h2l2 et hcab
CA3177918A1 (fr) 2020-07-01 2022-01-06 Amanda ATANASIO Methodes pour traiter l'allergie a l'aide d'anticorps anti-bet v 1
CN116194105A (zh) * 2020-09-14 2023-05-30 辉瑞大药厂 治疗癌症的方法、疗法及用途
WO2022060901A1 (fr) 2020-09-16 2022-03-24 Amgen Inc. Méthodes d'administration de doses thérapeutiques de molécules bispécifiques activant les lymphocytes t pour le traitement du cancer
EP4214234A1 (fr) 2020-09-18 2023-07-26 Regeneron Pharmaceuticals, Inc. Molécules de liaison à l'antigène se liant à cd38 et/ou cd28 et leurs utilisations
CN118878694A (zh) * 2020-11-23 2024-11-01 康诺亚生物医药科技（成都）有限公司 一种双特异性抗体及其用途
CN114573703A (zh) * 2020-12-02 2022-06-03 康诺亚生物医药科技（成都）有限公司 一种t细胞衔接器治疗剂的开发和应用
PH12023500013A1 (en) 2020-12-04 2024-03-11 Tidal Therapeutics Inc Ionizable cationic lipids and lipi nanoparticles, and methods of synthesis and use thereof
TW202246333A (zh) * 2021-01-20 2022-12-01 大陸商江蘇恆瑞醫藥股份有限公司 特異性結合ｂｃｍａ和ｃｄ３的抗原結合分子及其醫藥用途
RS66868B1 (sr) 2021-01-28 2025-06-30 Regeneron Pharma Kompozicije i postupci za lečenje sindroma oslobađanja citokina
CN115724996B (zh) * 2021-08-30 2026-03-20 上海君赛生物股份有限公司 含有膜表面结构域的多肽及其用途
CN118696058A (zh) 2021-12-03 2024-09-24 山东先声生物制药有限公司 抗bcma纳米抗体及其应用
CN118647724A (zh) * 2021-12-22 2024-09-13 杰克逊实验室 人源化小鼠模型
CA3247475A1 (fr) 2022-04-11 2023-10-19 Regeneron Pharmaceuticals, Inc. Compositions et méthodes permettant la destruction de cellule tumorale universelle
CN117003871A (zh) 2022-04-28 2023-11-07 北京天广实生物技术股份有限公司 结合bcma和cd3的抗体及其用途
CN119546644A (zh) 2022-05-18 2025-02-28 瑞泽恩制药公司 结合cd38和4-1bb的多特异性抗原结合分子及其用途
KR20250021313A (ko) 2022-06-06 2025-02-12 산둥심시어 바이오파마슈티칼 씨오., 엘티디. Bcma, gprc5d 및 t 세포를 표적으로 하는 다중특이적 항체 및 그 응용
AR129560A1 (es) 2022-06-08 2024-09-04 Tidal Therapeutics Inc Lípidos catiónicos ionizables y nanopartículas lipídicas, y métodos de síntesis y uso de los mismos
CN115368466A (zh) * 2022-07-19 2022-11-22 合肥天港免疫药物有限公司 双特异性抗体及其应用
CN120282798A (zh) 2022-10-10 2025-07-08 瑞泽恩制药公司 用于降低需要实体器官移植的受试者中的同种抗体水平的方法
CN117186230B (zh) * 2022-12-06 2024-04-16 成都赛恩吉诺生物科技有限公司 包含亲水性氨基酸的抗人bcma纳米抗体的双特异性抗体及应用
JP2026506095A (ja) 2023-02-17 2026-02-20 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｃｄ３／ｔａａ二重特異性抗体に応答する誘導ｎｋ細胞
AU2024279278A1 (en) 2023-05-31 2025-12-18 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
CN121335930A (zh) 2023-06-06 2026-01-13 信达生物制药(苏州)有限公司 抗gprc5d/bcma/cd3三特异性抗体的制备及其用途
TW202517293A (zh) 2023-07-07 2025-05-01 美商再生元醫藥公司 含有抗bcmax抗cd3雙特異性抗體之穩定化配製物
WO2025059362A1 (fr) 2023-09-13 2025-03-20 Juno Therapeutics, Inc. Polythérapies comprenant une thérapie cellulaire exprimant un car ciblant gprc5d, méthodes et utilisations associés
WO2025076113A1 (fr) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Lipides cationiques ionisables à espacement conservé et nanoparticules lipidiques
IL327045A (en) 2023-10-05 2026-05-01 Capstan Therapeutics Inc Structure-restricted ionizable cationic lipids and lipid nanoparticles
WO2025131075A1 (fr) * 2023-12-21 2025-06-26 上海君实生物医药科技股份有限公司 Anticorps multispécifiques anti-cd3 et anti-cd3, et utilisation
US20250242018A1 (en) 2024-01-26 2025-07-31 Regeneron Pharmaceuticals, Inc. Combination immunosuppression for inhibiting an immune response and enabling immunogen administration and re-administration
US20250242056A1 (en) 2024-01-26 2025-07-31 Regeneron Pharmaceuticals, Inc. Methods and compositions for using plasma cell depleting agents and/or b cell depleting agents to suppress host anti-aav antibody response and enable aav transduction and re-dosing
TW202543581A (zh) 2024-02-12 2025-11-16 美商艾伊拉醫療公司 遞送組成物
WO2025184567A1 (fr) 2024-03-01 2025-09-04 Regeneron Pharmaceuticals, Inc. Procédés et compositions pour redosage d'un aav à l'aide d'un anticorps antagoniste anti-cd40 pour supprimer une réponse d'anticorps anti-aav hôte
TW202543585A (zh) 2024-03-08 2025-11-16 美商健臻公司 脂質奈米粒子
WO2025217454A2 (fr) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Lipides cationiques ionisables et nanoparticules lipidiques
WO2025217452A1 (fr) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Lipides cationiques ionisables contraints et nanoparticules lipidiques
WO2025240287A1 (fr) 2024-05-13 2025-11-20 Regeneron Pharmaceuticals, Inc. Méthodes de traitement de l'amylose à chaîne légère avec des anticorps bispécifiques bcma x cd3
WO2025244973A1 (fr) 2024-05-20 2025-11-27 Regeneron Pharmaceuticals, Inc. Méthodes de traitement d'un myélome multiple avec des anticorps bispécifiques bcma x cd3
WO2026006492A2 (fr) 2024-06-25 2026-01-02 Ypsilon Therapeutics, Inc. Anticorps anti-prame/hla-a2 et leurs utilisations
WO2026006495A1 (fr) 2024-06-25 2026-01-02 Alloy Therapeutics, Inc. Anticorps anti-wt1/hla-a2 et ses utilisations
WO2026015729A1 (fr) 2024-07-11 2026-01-15 Regeneron Pharmaceuticals, Inc. Anticorps bispécifiques gprc5d x cd28 et leurs procédés d'utilisation
WO2026059919A1 (fr) 2024-09-10 2026-03-19 Regeneron Pharmaceuticals, Inc. Méthodes de traitement du myélome multiple avec des inhibiteurs de bcma en combinaison avec des inhibiteurs de cd38
WO2026059923A1 (fr) 2024-09-10 2026-03-19 Regeneron Pharmaceuticals, Inc. Méthodes de traitement du myélome multiple mettant en oeuvre des inhibiteurs du bcma en association avec un immunomodulateur
WO2026059920A1 (fr) 2024-09-10 2026-03-19 Regeneron Pharmaceuticals, Inc. Méthodes de traitement du myélome multiple avec des inhibiteurs de bcma en combinaison avec des inhibiteurs de pd1/pd-l1
WO2026059917A1 (fr) 2024-09-10 2026-03-19 Regeneron Pharmaceuticals, Inc. Méthodes de traitement du myélome multiple faisant appel à des inhibiteurs du bcma associés à des inhibiteurs du protéasome
WO2026059921A1 (fr) 2024-09-10 2026-03-19 Regeneron Pharmaceuticals, Inc. Méthodes de traitement du myélome multiple mettant en oeuvre des inhibiteurs du bcma en association avec des inhibiteurs de la lag3
WO2026072557A2 (fr) 2024-09-24 2026-04-02 Genzyme Corporation Nanoparticules lipidiques et lipides cationiques ionisables, leurs procédés de synthèse et méthodes d'utilisation
WO2026072671A1 (fr) 2024-09-24 2026-04-02 City Of Hope Procédés utilisant des virus oncolytiques exprimant le bcmat et thérapies ciblées anti-bcma
WO2026072709A1 (fr) 2024-09-25 2026-04-02 Orna Therapeutics, Inc. Récepteurs antigéniques chimériques ciblant bcma

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
ATE255131T1 (de) 1991-06-14 2003-12-15 Genentech Inc Humanisierter heregulin antikörper
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
PL211786B1 (pl) 1999-08-17 2012-06-29 Apoxis Sa Zastosowanie przeciwciała oraz polipeptydu
US20040002068A1 (en) 2000-03-01 2004-01-01 Corixa Corporation Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
JP4336498B2 (ja) 2000-12-12 2009-09-30 メディミューン，エルエルシー 延長した半減期を有する分子ならびにその組成物および用途
DE10206325A1 (de) 2002-02-14 2003-09-04 Medinnova Ges Med Innovationen Ummantelter Mikroorganismus
US7261893B2 (en) 2002-10-22 2007-08-28 Wyeth Neutralizing antibodies against GDF-8 and uses therefor
US7700099B2 (en) 2005-02-14 2010-04-20 Merck & Co., Inc. Non-immunostimulatory antibody and compositions containing the same
TW200732350A (en) 2005-10-21 2007-09-01 Amgen Inc Methods for generating monovalent IgG
NZ587107A (en) 2006-06-02 2012-05-25 Regeneron Pharma High affinity antibodies to human il-6 receptor
KR101589785B1 (ko) 2009-03-10 2016-01-28 바이오젠 엠에이 인코포레이티드 항-ｂｃｍａ 항체
LT2975051T (lt) 2009-06-26 2021-07-12 Regeneron Pharmaceuticals, Inc. Lengvai išskiriami bispecifiniai antikūnai su natyvios formos imunoglobulinu
HRP20151188T4 (hr) 2010-02-08 2021-10-01 Regeneron Pharmaceuticals, Inc. Miš sa zajedničkim lakim lancem
TWI667257B (zh) 2010-03-30 2019-08-01 中外製藥股份有限公司 促進抗原消失之具有經修飾的ＦｃＲｎ親和力之抗體
US20130273055A1 (en) 2010-11-16 2013-10-17 Eric Borges Agents and methods for treating diseases that correlate with bcma expression
TWI638833B (zh) 2010-11-30 2018-10-21 中外製藥股份有限公司 細胞傷害誘導治療劑
UA112434C2 (uk) 2011-05-27 2016-09-12 Ґлаксо Ґруп Лімітед Антигензв'язувальний білок, який специфічно зв'язується з всма
SI3415531T1 (sl) 2011-05-27 2023-12-29 Glaxo Group Limited Bcma (cd269/tnfrsf17) - vezni proteini
TWI679212B (zh) 2011-11-15 2019-12-11 美商安進股份有限公司 針對ｂｃｍａ之e3以及ｃｄ３的結合分子
ES3065694T3 (en) 2012-04-11 2026-05-07 Us Health Chimeric antigen receptors targeting b-cell maturation antigen
JOP20200236A1 (ar) * 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
ES2937015T3 (es) 2012-11-01 2023-03-23 Max Delbrueck Centrum Fuer Molekulare Medizin Helmholtz Gemeinschaft Anticuerpo contra CD269 (BCMA)
US9243058B2 (en) 2012-12-07 2016-01-26 Amgen, Inc. BCMA antigen binding proteins
TW201425336A (zh) 2012-12-07 2014-07-01 Amgen Inc Ｂｃｍａ抗原結合蛋白質
TWI682941B (zh) 2013-02-01 2020-01-21 美商再生元醫藥公司 含嵌合恆定區之抗體
US9963513B2 (en) 2013-02-05 2018-05-08 Engmab Sàrl Method for the selection of antibodies against BCMA
EP2762497A1 (fr) 2013-02-05 2014-08-06 EngMab AG Anticorps bispécifiques contre la CD3epsilon et BCMA
EP2762496A1 (fr) 2013-02-05 2014-08-06 EngMab AG Procédé pour la sélection d'anticorps contre BCMA
AR095374A1 (es) 2013-03-15 2015-10-14 Amgen Res Munich Gmbh Moléculas de unión para bcma y cd3
GB201317929D0 (en) 2013-10-10 2013-11-27 Ucl Business Plc Chimeric antigen receptor
US20180112384A1 (en) 2013-12-30 2018-04-26 Craig Rothleitner Drainage treatment system
KR102526945B1 (ko) 2014-04-30 2023-04-27 막스-델부뤽-센트럼 퓌어 몰레쿨라레 메디친 인 데어 헬름홀츠-게마인샤프트 Ｃｄ269에 대한 인간화 항체
MX2017001079A (es) 2014-07-24 2017-09-12 Bluebird Bio Inc Receptores de antígeno quiméricos de antígeno de maduración de células b (bcma).
EP2982692A1 (fr) * 2014-08-04 2016-02-10 EngMab AG Anticorps bispécifiques contre la CD3epsilon et BCMA
BR112017010513A2 (pt) 2014-11-20 2018-04-03 F. Hoffmann-La Roche Ag ?cadeias leves comuns e métodos de uso?
EP3029068A1 (fr) 2014-12-03 2016-06-08 EngMab AG Anticorps bispécifiques contre du CD3epsilon et BCMA pour utilisation dans le traitement de maladies
EP3872094A3 (fr) 2014-12-05 2021-12-08 Memorial Sloan Kettering Cancer Center Anticorps ciblant un antigène de maturation des lymphocytes b et procédés d'utilisation
SG11201704549UA (en) 2014-12-05 2017-07-28 Memorial Sloan Kettering Cancer Center Chimeric antigen receptors targeting b-cell maturation antigen and uses thereof
EP3971210A1 (fr) 2014-12-12 2022-03-23 2seventy bio, Inc. Composition utilisée dans le traitement d'affections liées aux cellules b chez un sujet en besoin, comprenant une cellule effective comportant des récepteurs d'antigènes chimériques bcma
TWI700298B (zh) 2015-04-13 2020-08-01 美商輝瑞股份有限公司 靶向ｂ細胞成熟抗原之嵌合型抗原受體類
IL310723A (en) 2015-04-13 2024-04-01 Pfizer Therapeutic antibodies and their uses
CA2985816A1 (fr) 2015-05-15 2016-11-24 The General Hospital Corporation Anticorps antagonistes de la superfamille du recepteur du facteur de necrose anti-tumoral
JOP20160154B1 (ar) 2015-07-31 2021-08-17 Regeneron Pharma أجسام ضادة مضاد لل psma، وجزيئات رابطة لمستضد ثنائي النوعية الذي يربط psma و cd3، واستخداماتها
WO2017031104A1 (fr) * 2015-08-17 2017-02-23 Janssen Pharmaceutica Nv Anticorps anti-bcma, molécules bispécifiques de liaison à un antigène liant bcma et cd3 et leurs utilisations
KR102777500B1 (ko) * 2015-09-23 2025-03-11 리제너론 파아마슈티컬스, 인크. 최적화된 항-cd3 이중특이적 항체 및 이의 용도
AU2016353067B2 (en) 2015-11-13 2023-10-05 Sanford Research Anti-BCMA polypeptides and proteins
US20190256608A1 (en) 2015-12-01 2019-08-22 Glaxosmithkline Intellectual Property Development Limited Combination treatments and uses and methods thereof
JOP20170017B1 (ar) 2016-01-25 2021-08-17 Amgen Res Munich Gmbh تركيب صيدلي يتضمن تركيبات جسم مضاد ثنائي الاختصاص
SG11201805770UA (en) 2016-02-03 2018-08-30 Amgen Res Munich Gmbh BCMA and CD3 Bispecific T Cell Engaging Antibody Constructs
IL311107A (en) 2016-02-17 2024-04-01 Seagen Inc BCMA antibodies and their use for the treatment of cancer and immune disorders
US10689450B2 (en) 2016-04-01 2020-06-23 Kite Pharma, Inc BCMA binding molecules and methods of use thereof
US12048718B2 (en) 2016-06-07 2024-07-30 Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Geminschaft Chimeric antigen receptor and CAR-T cells that bind BCMA
WO2018009904A2 (fr) 2016-07-08 2018-01-11 Tumeh Paul C Compositions et méthodes de traitement pour l'immunothérapie du cancer
MY200988A (en) 2016-09-14 2024-01-27 Teneobio Inc CD3 Binding Antibodies
US10738130B2 (en) * 2016-09-23 2020-08-11 Regeneron Pharmaceuticals, Inc. Bispecific antigen-binding molecules that bind MUC16 and CD3, and compositions thereof
WO2018075359A1 (fr) 2016-10-18 2018-04-26 Boger Henry William Transfert d'énergie sans fil destiné à une commande de processus
EP3535295A1 (fr) * 2016-11-02 2019-09-11 EngMab Sàrl Anticorps bispécifique contre bcma et cd3 et médicament immunologique pour une utilisation combinée dans le traitement du myélome multiple
WO2018099539A1 (fr) 2016-11-29 2018-06-07 Horst Lindhofer Combinaison d'anticorps multifonctionnels de redirection de lymphocytes (t) avec des modulateurs de point de contrôle immunitaires et leurs utilisations
KR102745676B1 (ko) 2016-12-21 2024-12-24 테네오바이오, 인코포레이티드 항-bcma 중쇄-단독 항체
JP7280828B2 (ja) 2017-01-23 2023-05-24 クレージュ メディカル カンパニー，リミテッド Ｂｃｍａを標的とする抗体およびその使用
CA3049689A1 (fr) 2017-02-06 2018-08-09 Dana-Farber Cancer Institute, Inc. Compositions et methodes pour augmenter la signalisation de recepteurs mediee par des anticorps
JP2020507605A (ja) 2017-02-17 2020-03-12 フレッド ハッチンソン キャンサー リサーチ センター Ｂｃｍａ関連癌および自己免疫疾患の治療のための併用療法
US20200179511A1 (en) 2017-04-28 2020-06-11 Novartis Ag Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
KR102700015B1 (ko) 2017-05-05 2024-08-29 암젠 인크 개선된 저장 및 투여를 위한 이중특이적 항체 구축물을 포함하는 약제학적 조성물
IL312322B2 (en) 2017-06-20 2026-05-01 Teneobio Inc Antibodies against BCMA containing only heavy chains
SG11202000499RA (en) 2017-08-01 2020-02-27 Medimmune Llc Bcma monoclonal antibody-drug conjugate
US11447559B2 (en) 2017-09-29 2022-09-20 Mogam Institute For Biomedical Research Anti-BCMA antibody having high affinity for BCMA and pharmaceutical composition for treatment of cancer, comprising same
SI3694529T1 (sl) 2017-10-13 2024-10-30 Harpoon Therapeutics, Inc. Trispecifične beljakovine in načini uporabe
CN107827989A (zh) 2017-10-18 2018-03-23 银丰生物工程集团有限公司 靶向骨髓瘤bcma抗原的转基因t细胞及其制备方法与应用
CN110709425B (zh) 2018-02-01 2022-09-16 南京驯鹿医疗技术有限公司 一种结合bcma的嵌合抗原受体（car）及其应用
CN112912397B (zh) * 2018-05-24 2025-03-14 詹森生物科技公司 抗cd3抗体及其用途
TWI838389B (zh) 2018-07-19 2024-04-11 美商再生元醫藥公司 雙特異性抗-BCMAｘ抗-CD3抗體及其用途
SG11202109002XA (en) * 2019-03-21 2021-09-29 Regeneron Pharma Combination of il-4/il-13 pathway inhibitors and plasma cell ablation for treating allergy

Also Published As

Publication number Publication date
SI3823664T1 (sl) 2025-03-31
EP4516810A3 (fr) 2025-07-16
EP3823664B1 (fr) 2025-01-08
MX2021000488A (es) 2021-04-12
TW202019966A (zh) 2020-06-01
US12258412B2 (en) 2025-03-25
FIC20253006I1 (fi) 2025-08-14
LT3823664T (lt) 2025-02-25
HRP20250199T1 (hr) 2025-04-11
CN112423785B (zh) 2025-03-04
BR112021000186A2 (pt) 2021-08-10
ES3010285T3 (en) 2025-04-02
EP4516810A2 (fr) 2025-03-05
AU2019307928B2 (en) 2025-09-25
TWI838389B (zh) 2024-04-11
FR25C1029I1 (fr) 2025-09-26
FR25C1029I2 (fr) 2026-03-27
NO2025036I1 (no) 2025-08-07
SMT202500044T1 (it) 2025-03-12
US20260008862A1 (en) 2026-01-08
JP2023134728A (ja) 2023-09-27
IL279974B1 (en) 2025-03-01
CA3107126A1 (fr) 2020-01-23
MX2025005515A (es) 2025-06-02
HUE070224T2 (hu) 2025-05-28
HUS2500032I1 (hu) 2025-09-28
JP7319348B2 (ja) 2023-08-01
PT3823664T (pt) 2025-01-24
PH12021550031A1 (en) 2021-09-20
NL301335I2 (nl) 2025-09-10
PL3823664T3 (pl) 2025-03-17
MD3823664T2 (ro) 2025-06-30
DK3823664T3 (da) 2025-02-17
CN112423785A (zh) 2021-02-26
CY2025020I2 (el) 2026-02-25
MA53168A (fr) 2021-05-26
CO2021000188A2 (es) 2021-01-18
LTPA2025526I1 (fr) 2025-07-25
IL279974A (en) 2021-03-01
JP2021531005A (ja) 2021-11-18
US20200024356A1 (en) 2020-01-23
AU2019307928A1 (en) 2021-02-11
ZA202100087B (en) 2025-07-30
RS66535B1 (sr) 2025-03-31
JP7586974B2 (ja) 2024-11-19
CY2025020I1 (el) 2026-02-25
SG11202100252SA (en) 2021-02-25
MY201816A (en) 2024-03-19
US11384153B2 (en) 2022-07-12
CL2021000131A1 (es) 2021-07-02
CY1127721T1 (el) 2026-02-25
EP3823664A1 (fr) 2021-05-26
KR20210034032A (ko) 2021-03-29
IL279974B2 (en) 2025-07-01
US20220306758A1 (en) 2022-09-29
FI3823664T3 (fi) 2025-03-04
WO2020018820A1 (fr) 2020-01-23

Similar Documents

Publication Publication Date Title
MX2025005515A (es) Anticuerpos anti-bcma x anti-cd3 biespecificos y usos de estos
MA42935B1 (fr) Anticorps bispécifiques anti-cd3 optimisés et leurs utilisations
MA49043B1 (fr) Formulation stable d'anticorps
Mishra et al. Anti-ADAM17 monoclonal antibody MEDI3622 increases IFNγ production by human NK cells in the presence of antibody-bound tumor cells
MA65527B1 (fr) Récepteurs antigéniques chimériques possédant une spécificité pour le bcma, et utilisations correspondantes
Huergo-Zapico et al. Expression of ERp5 and GRP78 on the membrane of chronic lymphocytic leukemia cells: association with soluble MICA shedding
Wan et al. Hyperfunction of CD4 CD25 regulatory T cells in de novo acute myeloid leukemia
Niu et al. In vitro analysis of the proliferative capacity and cytotoxic effects of ex vivo induced natural killer cells, cytokine-induced killer cells, and gamma-delta T cells
ZA201901591B (en) Anti¿muc16 (mucin 16) antibodies
PH12020551153A1 (en) Antibodies specific for cd70 and their uses
LU91616I2 (fr) Anticorps monoclonal hybride rat-souris(IgG2) soustoutes les formes couvertes par le brevet de base (REMOVAB - Catumaxomab)
JP6868655B2 (ja) Ｃｄ６結合パートナーの使用およびそれに基づく方法
WO2021207242A3 (fr) Molécules de liaison à l'antigène anti-mésothéline et leurs utilisations
D’Arena et al. Regulatory T-cells in chronic lymphocytic leukemia: actor or innocent bystander?
Ding et al. Nanobody-based trispecific T cell engager (Nb-TriTE) enhances therapeutic efficacy by overcoming tumor-mediated immunosuppression
Billard et al. Switch in the protein tyrosine phosphatase associated with human CD100 semaphorin at terminal B-cell differentiation stage
Thibult et al. CpG-ODN-induced sustained expression of BTLA mediating selective inhibition of human B cells
CL2024003480A1 (es) Moléculas multiespecíficas de unión a antígeno que se unen a cd38 y 4-1bb, y usos de las mismas.
Tukaj et al. Autologous extracellular Hsp70 exerts a dual role in rheumatoid arthritis
Madondo et al. Variability in CRP, regulatory T cells and effector T cells over time in gynaecological cancer patients: a study of potential oscillatory behaviour and correlations
MY204368A (en) Anti-fc epsilon-r1 alpha (fcer1a) antibodies, bispecific antigen-binding molecules that bind fcer1a and cd3, and uses thereof
Jurišić et al. The role of NK cells in cancer
EA202190314A1 (ru) Биспецифические анти-bcma x анти-cd3 антитела и способы их применения
King et al. PD-L1 directed bispecific Vδ2-T cell engager combines lysis of PD-L1 expressing tumor cells with PD-1 immune checkpoint inhibition and modulation of the tumor immune microenvironment
MA46281B1 (fr) Anticoprs anti muc16 (mucin 16)